We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$256M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
96.01%
Top 10 Hldgs %
29.36%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.6M
2
CELG
Celgene Corp
CELG
+$7.75M
3
GILD icon
Gilead Sciences
GILD
+$7.59M
4
PCYC
PHARMACYCLICS INC
PCYC
+$7.28M
5
BIIB icon
Biogen
BIIB
+$6.98M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 82.65%
2 Financials 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
76
Cardiff Oncology
CRDF
$77.2M
$1.15M 0.45%
+2,778
New +$1.24M
VOLC
77
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$983K 0.38%
+45,000
New +$997K
LUMO
78
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$880K 0.34%
+4,444
New +$790K
MDRX
79
DELISTED
Veradigm Inc. Common Stock
MDRX
$850K 0.33%
+55,000
New +$810K
LXRX icon
80
Lexicon Pharmaceuticals
LXRX
$1.1B
$540K 0.21%
+42,857
New +$682K
MDGL icon
81
Madrigal Pharmaceuticals
MDGL
$11.8B
$524K 0.21%
+2,857
New +$523K
NVDQ
82
DELISTED
Novadaq Technologies Inc.
NVDQ
$412K 0.16%
+25,000
New +$414K
ANTH
83
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$366K 0.14%
+14,912
New +$384K
ECYT
84
DELISTED
Endocyte, Inc. Common Stock
ECYT
$267K 0.1%
+25,000
New +$276K
1 2 3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Rhenman & Partners Asset Management, which disclosed 84 positions worth $256M. Its ten largest holdings account for 29% of the portfolio.

Its largest position is Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q4 2013 buy was Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $256M portfolio in Q4 2013.
  • Rhenman & Partners Asset Management disclosed 84 positions in Q4 2013, its first 13F filing on record.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.